{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["30(8)"],"submitter":["Ai J"],"pubmed_abstract":["The SARS-CoV-2 Omicron variant has evolved into four sub-lineages-BA.1, BA.1.1, BA.2, and BA.3-with BA.2 becoming dominant worldwide. We and others have reported antibody evasion of BA.1 and BA.2, but side-by-side comparisons of Omicron sub-lineages to vaccine-elicited or monoclonal antibody (mAb)-mediated neutralization are necessary. Using VSV-based pseudovirus, we report that sera from individuals vaccinated by two doses of an inactivated whole-virion vaccine shows weak to no neutralization activity, while homologous or heterologous boosters markedly improve neutralization titers against all Omicron sub-lineages. We also present neutralization profiles against a 20 mAb panel, including 10 authorized or approved, against the Omicron sub-lineages, along with mAb mapping against single or "],"journal":["Cell host & microbe"],"pagination":["1077-1083.e4"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9080084"],"repository":["biostudies-literature"],"pubmed_title":["Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages."],"pmcid":["PMC9080084"],"pubmed_authors":["Yang L","Hu Z","Ai J","Li L","Li M","Zhao X","Jiang Y","Zhang W","Li Y","Wang P","Qiao R","Zhang Y","Cui Y","He X","Chen Y","Wang X"],"additional_accession":[]},"is_claimable":false,"name":"Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages.","description":"The SARS-CoV-2 Omicron variant has evolved into four sub-lineages-BA.1, BA.1.1, BA.2, and BA.3-with BA.2 becoming dominant worldwide. We and others have reported antibody evasion of BA.1 and BA.2, but side-by-side comparisons of Omicron sub-lineages to vaccine-elicited or monoclonal antibody (mAb)-mediated neutralization are necessary. Using VSV-based pseudovirus, we report that sera from individuals vaccinated by two doses of an inactivated whole-virion vaccine shows weak to no neutralization activity, while homologous or heterologous boosters markedly improve neutralization titers against all Omicron sub-lineages. We also present neutralization profiles against a 20 mAb panel, including 10 authorized or approved, against the Omicron sub-lineages, along with mAb mapping against single or ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-05-18T11:37:55.092Z","creation":"2025-02-19T04:20:59.382Z"},"accession":"S-EPMC9080084","cross_references":{"pubmed":["35594867"],"doi":["10.1016/j.chom.2022.05.001"]}}